前のページに戻る この文献は全文を取り寄せることができます
JDreamⅢ複写サービスから文献全文の複写（冊子体のコピー）をお申込みできます。
ご利用には、G-Searchデータベースサービスまたは、JDreamⅢのIDが必要です。
既に、G-Searchデータベースサービスまたは、JDreamⅢのIDをお持ちの方
JDreamⅢ複写サービス
文献複写のお申込み
JDreamⅢ複写サービスのご利用が初めての方
学術文献の全文複写をお取寄せ
JDreamⅢ複写サービスのご案内
取り寄せる文献のタイトルと詳細
文献
J-GLOBAL ID：202102276057797267   整理番号：21A0023570

移植前MRD陰性度は,再発性/難治性急性リンパ芽球性白血病に対する,CAR-T療法の良好な転帰を予測する: 多施設後向き研究【JST・京大機械翻訳】

Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study
著者 (59件)：
Zhao Houli
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
, 
Zhao Houli
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
, 
Zhao Houli
(Institute of Hematology, Zhejiang University, Hangzhou, China)
, 
Wei Jieping
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
, 
Wei Jieping
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
, 
Wei Jieping
(Institute of Hematology, Zhejiang University, Hangzhou, China)
, 
Wei Guoqing
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
, 
Wei Guoqing
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
, 
Wei Guoqing
(Institute of Hematology, Zhejiang University, Hangzhou, China)
, 
Luo Yi
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
, 
Luo Yi
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
, 
Luo Yi
(Institute of Hematology, Zhejiang University, Hangzhou, China)
, 
Shi Jimin
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
, 
Shi Jimin
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
, 
Shi Jimin
(Institute of Hematology, Zhejiang University, Hangzhou, China)
, 
Cui Qu
(Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China)
, 
Zhao Mingfeng
(Department of Hematology, Tianjin First Central Hospital, Tianjin, China)
, 
Liang Aibin
(Department of Hematology, Shanghai Tongji Hospital, Shanghai, China)
, 
Zhang Qing
(Department of Hematology, Guangdong Second Provincial General Hospital, Guangzhou, China)
, 
Yang Jianmin
(Department of Hematology, Changhai Hospital of Shanghai, Shanghai, China)
, 
Li Xin
(Department of Hematology, Xiangya Third Hospital, Changsha, China)
, 
Chen Jing
(Department of Hematology, Shanghai Children’s Medical Center, Shanghai, China)
, 
Song Xianmin
(Department of Hematology, Shanghai General Hospital, Shanghai, China)
, 
Jing Hongmei
(Department of Hematology, Peking University Third Hospital, Beijing, China)
, 
Li Yuhua
(Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou, China)
, 
Hao Siguo
(Department of Hematology, Xinhua Hospital of Shanghai, Shanghai, China)
, 
Wu Wenjun
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
, 
Wu Wenjun
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
, 
Wu Wenjun
(Institute of Hematology, Zhejiang University, Hangzhou, China)
, 
Tan Yamin
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
, 
Tan Yamin
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
, 
Tan Yamin
(Institute of Hematology, Zhejiang University, Hangzhou, China)
, 
Yu Jian
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
, 
Yu Jian
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
, 
Yu Jian
(Institute of Hematology, Zhejiang University, Hangzhou, China)
, 
Zhao Yanmin
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
, 
Zhao Yanmin
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
, 
Zhao Yanmin
(Institute of Hematology, Zhejiang University, Hangzhou, China)
, 
Lai Xiaoyu
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
, 
Lai Xiaoyu
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
, 
Lai Xiaoyu
(Institute of Hematology, Zhejiang University, Hangzhou, China)
, 
Yin Elaine Tan Su
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
, 
Yin Elaine Tan Su
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
, 
Yin Elaine Tan Su
(Institute of Hematology, Zhejiang University, Hangzhou, China)
, 
Wei Yunxiong
(Department of Hematology, Tianjin First Central Hospital, Tianjin, China)
, 
Li Ping
(Department of Hematology, Shanghai Tongji Hospital, Shanghai, China)
, 
Huang Jing
(Department of Hematology, Guangdong Second Provincial General Hospital, Guangzhou, China)
, 
Wang Tao
(Department of Hematology, Changhai Hospital of Shanghai, Shanghai, China)
, 
Blaise Didier
(Institut Paoli-Calmettes, Marseille, France)
, 
Xiao Lei
(Innovative Cellular Therapeutics Co, Ltd, Shanghai, China)
, 
Chang Alex H.
(Shanghai YaKe Biotechnology Ltd, Shanghai, China)
, 
Nagler Arnon
(Hematology and Bone Marrow Transplantation Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel)
, 
Mohty Mohamad
(Sorbonne University, Saint-Antoine Hospital, INSERM UMRs 938, Paris, France)
, 
Huang He
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
, 
Huang He
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
, 
Huang He
(Institute of Hematology, Zhejiang University, Hangzhou, China)
, 
Hu Yongxian
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
, 
Hu Yongxian
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
, 
Hu Yongxian
(Institute of Hematology, Zhejiang University, Hangzhou, China)

資料名：
Journal of Hematology & Oncology (Web)  (Journal of Hematology & Oncology (Web))

巻： 13  号： 1  ページ： 1-13  発行年： 2020年 
JST資料番号： U7517A  ISSN： 1756-8722  資料種別： 逐次刊行物 (A)
記事区分： 短報  発行国： イギリス (GBR)  言語： 英語 (EN)
JDreamⅢ複写サービスとは
JDreamⅢ複写サービスは、学術文献の全文を複写（コピー）して取り寄せできる有料サービスです。インターネットに公開されていない文献や、図書館に収録されていない文献の全文を、オンラインで取り寄せることができます。J-GLOBALの整理番号にも対応しているので、申し込みも簡単にできます。全文の複写（コピー）は郵送またはFAXでお送りします

※ご利用には、G-Searchデータベースサービスまたは、JDreamⅢのIDが必要です
※初めてご利用される方は、JDreamⅢ複写サービスのご案内をご覧ください。

Copyright (c) 2009 Japan Science and Technology Agency. All Rights Reserved

TOP

BOTTOM